Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT03430011 · COMPLETED
Trial details
- NCT number
- NCT03430011
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-01
- Primary completion
- 2023-03-30
- Enrollment
- 165
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.